FY2024 Earnings Estimate for KROS Issued By HC Wainwright

Keros Therapeutics, Inc. (NASDAQ:KROS) – Stock analysts at HC Wainwright cut their FY2024 earnings estimates for Keros Therapeutics in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($5.36) per share for the year, down from their prior forecast of ($4.64). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($5.14) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q4 2024 earnings at ($1.48) EPS, Q1 2025 earnings at ($1.51) EPS, Q2 2025 earnings at ($1.57) EPS, Q3 2025 earnings at ($1.54) EPS, Q4 2025 earnings at ($1.59) EPS, FY2025 earnings at ($6.21) EPS, FY2026 earnings at ($7.15) EPS, FY2027 earnings at ($8.41) EPS and FY2028 earnings at ($5.79) EPS.

Other research analysts have also issued research reports about the company. Scotiabank assumed coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price target on the stock. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating on the stock. Cantor Fitzgerald assumed coverage on shares of Keros Therapeutics in a research note on Thursday, October 24th. They issued an “overweight” rating for the company. Bank of America decreased their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a report on Thursday. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $88.89.

Keros Therapeutics Stock Performance

KROS opened at $67.91 on Monday. The business’s 50-day simple moving average is $58.19 and its 200 day simple moving average is $52.16. Keros Therapeutics has a 52-week low of $27.31 and a 52-week high of $73.00. The firm has a market capitalization of $2.55 billion, a PE ratio of -13.03 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Keros Therapeutics’s quarterly revenue was up 4750.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.33) earnings per share.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its stake in shares of Keros Therapeutics by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock valued at $80,666,000 after acquiring an additional 176,803 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Keros Therapeutics during the second quarter worth approximately $1,118,000. Bank of New York Mellon Corp raised its position in shares of Keros Therapeutics by 18.8% in the second quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock valued at $5,410,000 after buying an additional 18,755 shares in the last quarter. Swiss National Bank boosted its stake in shares of Keros Therapeutics by 22.0% in the first quarter. Swiss National Bank now owns 49,900 shares of the company’s stock valued at $3,303,000 after buying an additional 9,000 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in Keros Therapeutics during the second quarter worth approximately $532,000. Institutional investors own 71.56% of the company’s stock.

Insider Buying and Selling

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares in the company, valued at $5,260,163.22. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 22.90% of the stock is currently owned by insiders.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.